Table: Santen Pharm -Q1 group results (IFRS)
05/08/2020 07:00
Aug 5 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2020 Jun 30, 2019 Mar 31, 2021
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 57.56 59.14 235.00
(-2.7 pct) (+4.7 pct) (-2.7 pct)
Operating 8.02 9.25 35.00
(-13.3 pct) (-7.7 pct) (+4.4 pct)
Pretax 8.36 9.00 34.00
(-7.1 pct) (-4.8 pct) (+5.9 pct)
Net 6.19 6.40
(-3.3 pct) (-6.6 pct)
EPS Basic 15.49 yen 16.03 yen 58.35 yen
EPS Diluted 15.46 yen 15.99 yen
Ann Div 27.00 yen 28.00 yen
-Q2 Div 13.00 yen 14.00 yen
-Q4 Div 14.00 yen 14.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T